Pimecrolimus does not affect Langerhans cells in murine epidermis

@article{Meingassner2003PimecrolimusDN,
  title={Pimecrolimus does not affect Langerhans cells in murine epidermis},
  author={Josef G. Meingassner and Elisabeth Kowalsky and Herbert Schwendinger and Adelheid Elbe-B{\"u}rger and Anton St{\"u}tz},
  journal={British Journal of Dermatology},
  year={2003},
  volume={149}
}
Background  Langerhans cells (LCs) function as specialized antigen‐presenting cells in the epidermis, and therefore play a critical role in cutaneous immunological reactions. Topical treatment with corticosteroids is associated with a decrease in epidermal LC number and antigen‐presenting capacity in laboratory animals and humans. 

Inflammatory cell numbers and cytokine expression in atopic dermatitis after topical pimecrolimus treatment

The purpose of this study was to investigate the effect of pimecrolimus on the inflammatory infiltrate and cytokine expression pattern in AD upon topical therapy.

Pimecrolimus versus topical corticosteroids in dermatology

The possibility that pimecrolimus deserves a greater role in the long-term treatment of skin diseases is discussed herein by reviewing the published clinical studies that compare pimeCrolimus and corticosteroids.

Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells.

The data show for the first time that CS but not pimecrolimus induce apoptosis in LC in situ, implying that the prolonged use of CS could have adverse effects on the skin immune system.

Differential effects of corticosteroids and pimecrolimus on the developing skin immune system in humans and mice.

The data suggest that similar to the situation in adult skin, corticosteroids may impair LC maturation as well as viability of ECs in infants, effects not seen with PIM.

Immunomodulation and Safety of Topical Calcineurin Inhibitors for the Treatment of Atopic Dermatitis

Preclinical and clinical data suggest a greater skin selectivity and larger safety margin for topical pimecrolimus, a safe and effective alternative to topical corticosteroids in children with mild and moderate AD.

Treatment of atopic dermatitis with pimecrolimus – impact on quality of life

Data which has assessed the impact of AD on the patient’s quality of life, and the consequent role of topical anti-inflammatory therapy for long-term AD treatment are discussed.

Update on the use of topical calcineurin inhibitors in cutaneous lupus erythematosus

The two available compounds, pimecrolimus and tacrolimus, do not induce the skin atrophy characteristic of corticosteroids, and are well-tolerated, but differentially effective in the various subsets of CLE.

Topical pimecrolimus in the treatment of genital lichen planus: a prospective case series

To the authors' knowledge, pimecrolimus has not been used in the treatment of GLP, and there is impairment of Langerhans cell function, raising concerns about its long‐term use.
...

References

SHOWING 1-10 OF 18 REFERENCES

Langerhans cells—a reduction in numbers and their reappearance following steroid and cytotoxic therapy in humans

Epidermal Langerhans cells (LC) stained by antibodies to Ia, T6 and S‐100 showed sustained reduction in numbers following the application of betamethasone‐17‐valerate 0·05% cream to normal human skin, which remained until a return to almost normal cell numbers following cessation of the steroid.

Effects of topical corticosteroid therapy on Langerhans cell antigen presenting function in human skin

The results demonstrate that the anti‐inflammatory action of topical corticosteroids in man is associated not only with a reduction in the number of HLA‐DR/T6 positive LCs, but also with a marked decrease in Langerhans cell‐dependent T lymphocyte activation.

Cutaneous dendritic cells in the crossfire between innate and adaptive immunity.

  • B. Nickoloff
  • Biology, Medicine
    Journal of dermatological science
  • 2002

SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis

Background SDZ ASM 981 is a selective inhibitor of the production of pro‐inflammatory cytokines from T cells and mast cells in vitro. It is the first ascomycin macrolactam derivative under

Removal of the majority of epidermal Langerhans cells by topical or systemic steroid application enhances the effector phase of murine contact hypersensitivity.

The data suggest that resident LC are not the relevant APC in the effector phase ofCHS and that they may even provide down-regulatory, rather than stimulatory, signals during elicitation of CHS.

Effects of physicochemical agents on murine epidermal Langerhans cells and Thy-1-positive dendritic epidermal cells.

The selective removal of either of these two dendritic epidermal cell populations by physicochemical agents may provide an excellent strategy to further clarify the functional properties of both LC and Thy-1+DEC.

First experience of topical SDZ ASM 981 in children with atopic dermatitis

Background SDZ ASM 981 is a selective inhibitor of inflammatory cytokine release under development for the topical treatment of atopic dermatitis.

New staining techniques for the Langerhans cell.

Three new techniques are described for staining the Langerhans cell in whole mounts of fresh human and guinea pig epidermis, using paraphenylenediamine, gold sodium thiomalate and cobalt chloride in conjunction with a modified adenosine triphosphatase stain.